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Abstract Diabetes strongly predisposes to cardiovascular
disease (CVD), the leading cause of mortality in these
patients, as well as in the entire population. Hyperglycemia
is an important cardiovascular risk factor as shown by the
observation that even transient periods of hyperglycemia,
despite return to normoglycemia during follow-up, increase
the risk for CVD, a phenomenon termed ‘hyperglycemic
memory’. The molecular mechanisms underlying this
phenomenon remain largely unknown. As inflammation
plays an important role in the pathogenesis of atheroscle-
rosis, we propose that long-term functional reprogramming
of monocytes and macrophages, induced by hyper-
glycemia, plays an important role in the phenomenon of
hyperglycemic memory leading to cardiovascular compli-
cations in patients with diabetes. In this review, we discuss
recent insights showing that innate immune cells possess
the capacity to reprogram their function through epige-
netically mediated rewiring of gene transcription, a process
termed ‘trained immunity’. The long-term reprogramming
of monocytes can be induced by microbial as well as
metabolic products, and involves a shift in cellular meta-
bolism from oxidative phosphorylation to aerobic
glycolysis. We hypothesize that hyperglycemia in diabetes
patients induces long-term activation of monocytes and
macrophages through similar mechanisms, thereby con-
tributing to plaque development and subsequent
macrovascular complications.
Keywords Diabetes  Hyperglycemia  Atherosclerosis 
Trained immunity  Inflammation  Epigenetics 
Metabolism
Abbreviations
AGE Advanced glycation end product
AMPK AMP-activated protein kinase
BCG Bacillus Calmette–Gue´rin
CLR C-type lectin receptor
CVD Cardiovascular diseases
DCCT/EDIC Diabetes Control and Complications Trial
and Epidemiology of Diabetes Interventions
and Complications study
FFA Free fatty acid
GLUT1 Glucose transporter 1
H3K4me1 Histone H3 lysine 4 monomethylation
H3K4me3 Histone H3 lysine 4 trimethylation
H2K27Ac Histone H2 lysine 27 acetylation
H3K9me2 Histone H3 lysine 9 dimethylation
HbA1c Hemoglobin A1c
IL-6 Interleukin 6
LPS Lipopolysaccharide
MCP-1 Monocyte chemoattractant protein-1
NF-jB Nuclear factor jB
oxLDL Oxidized low density lipoprotein
PMA Phorbol 12-myristate 13-acetate
ROS Reactive oxygen species
PRR Pattern recognition receptor
& Janna A. van Diepen
janna.vandiepen@radboudumc.nl
1 Department of Internal Medicine, Radboud Institute for
Molecular Life Sciences, Radboud University Nijmegen
Medical Center, Radboudumc, (463), P. O. Box 9101,
6500 HB Nijmegen, The Netherlands
2 Nutrition, Metabolism and Genomics Group, Division of
Human Nutrition, Wageningen University, 6703 HA
Wageningen, The Netherlands
3 Radboud Center for Infectious Diseases, Radboud University
Nijmegen Medical Center, 6525 GA Nijmegen,
The Netherlands
Cell. Mol. Life Sci. (2016) 73:4675–4684
DOI 10.1007/s00018-016-2316-9 Cellular and Molecular Life Sciences
123
TLR Toll-like receptor
T1D Type 1 diabetes
T2D Type 2 diabetes
TNFa Tumor necrosis factor a
TXNIP Thioredoxin-interacting protein
UKPDS United Kingdom Prospective Diabetes
Study
VCAM-1 Vascular cell adhesion molecule 1
Introduction
There are 422 million people with diabetes worldwide and
probably many more individuals with undiagnosed dia-
betes. The presence of diabetes severely augments the risk
for atherosclerosis and associated cardiovascular diseases
(CVD), making cardiovascular disease the leading cause of
morbidity and mortality in individuals diagnosed with type
1 diabetes (T1D) or type 2 diabetes mellitus (T2D), as well
as the entire population. Multiple risk factors have been
described to contribute to diabetic complications, such as
genetic predisposition [1], dyslipidemia [2], and hyper-
tension [3], which cause proatherogenic processes in
diabetes patient’s independent of hyperglycemia.
Nonetheless, several prospective studies have revealed that
hyperglycemia per se, a defining characteristic of diabetes,
is an important and independent risk factor for cardiovas-
cular disease in patients with T1D and T2D [4–6]. Indeed,
among individuals with diabetes, a 1 % rise in hemoglobin
A1c (HbA1c) levels is associated with a 31 % increase in
cardiovascular events [7].
The importance of hyperglycemia as a risk factor is also
demonstrated by the observation that a period of elevated
HbA1c levels in the past translates into a higher future
incidence of CVD despite return to normoglycemia during
follow-up [4, 8]. Thus, the Diabetes Control and Compli-
cations Trial and Epidemiology of Diabetes Interventions
and Complications (DCCT/EDIC) study have played a
pivotal role in shaping our understanding of glycemic
control. Indeed, the DCCT showed that intensive glucose-
lowering therapy strongly reduced HbA1c levels compared
with the conventional therapy. After a mean follow-up of
6.5 years, the cohort was subsequently transferred to the
EDIC trial, where all patients were encouraged to intensive
glucose-lowering therapy and within 1 year, glycemic
control had become similar in both groups. Unexpectedly,
and thus, despite almost equal glycemic control during the
EDIC follow-up, the original conventional therapy group
continued to develop microvascular and macrovascular
complications at a higher rate than the group initially
assigned intensive therapy. This persistent risk for com-
plications observed for T1D patients in the DCCT/EDIC
trial has also been found in T2D patients in the United
Kingdom Prospective Diabetes Study (UKPDS) trial and
subsequently been defined as ‘hyperglycemic memory’ or
the ‘legacy effect’ [8, 9]. A growing body of evidence now
suggests that adverse effects of prior hyperglycemia are
‘memorized’ by vascular cells or tissues over time, trans-
lating into an enhanced risk for CVD. The molecular
mechanisms responsible for this hyperglycemic memory
are still far from understood, although epigenetic mecha-
nisms are thought to underlie this phenomenon [10, 11].
Epigenetic modifications refer to modifications in
chromatin state or non-coding RNAs that may lead to long-
term reprogramming in gene expression without changing
the nucleotide sequence of the DNA itself. Prior episodes
of hyperglycemia associate with epigenetic changes in
various vascular cell types in vitro and ex vivo (i.e., smooth
muscle cells and endothelial cells) conferring cell memo-
ries and may be of critical importance in the development
and progression of vascular complications, as reviewed
elsewhere [11–13]. It has only been recently shown that
monocytes and macrophages, guardians of non-specific
host defense, can also build up long-term memory via
epigenetic reprogramming, a process termed ‘trained
immunity’ [14, 15]. Innate immune cells are major regu-
lators of atherosclerotic plaque development and
progression [16]. Therefore, insights into mechanisms
controlling (long-term) activation of innate immune cells,
especially in diabetes patients, are of crucial importance to
understanding persistent vascular complications.
In the current review, we address the current knowledge
on the activation of monocytes and macrophages in
patients with diabetes in general and by hyperglycemic
conditions specifically. Subsequently, we discuss recent
novel insights into mechanisms implicated in long-term
activation and memory of monocytes and macrophages,
defined as trained immunity. We finally propose that
reprogramming of monocytes by hyperglycemia may
contribute to the hyperglycemic memory as an inducer of
vascular complications in patients with diabetes.
Hyperglycemia associates with monocyte
activation to contribute to the pathogenesis
of atherosclerosis
Initially viewed as primarily the result of lipid accumula-
tion, atherosclerotic development is currently considered as
a low-grade inflammatory disease of the arterial wall.
Altered monocyte and macrophage numbers, function, and
skewed proinflammatory signaling are considered to
facilitate vascular inflammation [16]. In the process of
atherosclerotic plaque formation, circulating monocytes
bind to activated endothelial cells, and transmigrate into
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the subendothelial space of the arterial wall where matu-
ration into macrophages occurs [17]. Macrophages express
scavenger receptors for uptake of modified lipoproteins
leading to foam cell formation. In addition, resident mac-
rophages are major contributors to the local inflammatory
response through secretion of proinflammatory mediators,
including chemokines, cytokines, and reactive oxygen
species (ROS) [16]. Both macrophage numbers and their
inflammatory phenotype influence plaque fate [16].
Circulating monocyte numbers and function
in diabetes patients
In high-risk populations, the amount of circulating
monocytes independently predicts the risk for coronary
artery disease [18–20]. In diabetes subjects, monocyte
counts are increased in T2D, but not T1D patients
[21, 22]. It would be interesting to investigate whether
subsets of monocytes are affected in T1D patients, espe-
cially because animal studies show that hyperglycemia
specifically increases inflammatory Ly6-Chi monocytes,
whereas non-inflammatory Ly6-Clo monocytes were lar-
gely unaffected [23].
Functional alterations have been observed in monocytes
isolated from both T2D and T1D patients. Monocyte
activation in T2D patients has been associated ex vivo with
enhanced inflammasome activation, known to activate
caspase-1 ultimately leading to proteolytic cleavage and
activation IL-1b and IL-18 [24]. Indeed, monocytes of T2D
patients also show increased proinflammatory interleukin
(IL)-1b and ROS secretion upon activation [25, 26], as well
as enhanced adhesion to the endothelium [26]. T2D is
frequently accompanied by multiple cardiovascular risk
factors, such as obesity, dyslipidemia and/or high blood
pressure, which also affect monocyte number and function
[27]. Therefore, to investigate the direct relation between
hyperglycemia and monocyte activation, findings in T1D
patient are easier to interpret. Monocytes from T1D
patients show increased release of proinflammatory
cytokines IL-6, IL-1b, and tumor necrosis factor a (TNFa)
after ex vivo activation of monocytes by interferon c
(IFNc) or lipopolysaccharide (LPS) [28, 29]. In addition,
binding of monocytes to cultured endothelial cells has been
shown to be increased in T1D patients [30], although this
could not be confirmed by others [28]. Importantly, the
adhesion of monocytes to endothelial cells may depend on
the level of hyperglycemia, since monocytes derived from
poorly controlled diabetes patients show higher binding to
endothelial cells than monocytes from well-controlled
patients [31] implying an important role of glucose in
activation of innate immune cells.
Relevance for CVD
The proinflammatory phenotype of monocytes with
increased binding to endothelium is expected to increase
monocyte migration in atherosclerotic plaques [32]. Autopsy
studies indeed reveal that plaques from patients with T1D
and T2D are characterized by enhanced macrophage infil-
tration [33]. Interestingly, plaque macrophage content was
associated with HbA1c levels, independently of any other
risk factors (e.g., plasma cholesterol levels), suggesting a
direct link between hyperglycemia and plaque macrophage
infiltration [33]. A recent study investigated expression of
proinflammatory and anti-inflammatory cytokines in both
monocytes as well as atherosclerotic plaque material derived
from T2D patients undergoing carotid endarterectomy.
Despite a somewhat underpowered study design, the authors
reported a positive correlation between HbA1c levels and
proinflammatory signaling in both circulating monocytes as
well as atherosclerotic plaques, as determined by an
increased ratio between proinflammatory IL-6 and TNFa
versus anti-inflammatory IL-10 expression [34].
Hyperglycemia and monocyte activation
Experimental murine and in vitro cell culture studies have
shed more light on possible mechanisms that may explain
the effect of hyperglycemia on monocyte activation. Peri-
toneal macrophages isolated from T1D and T2D mouse
models show increased proinflammatory cytokine expres-
sion [35]. Recent studies in animals show that glucose itself
enhances diabetes-associated atherosclerosis by promoting
proliferation and proinflammatory responses of innate
immune cells and their bone marrow progenitors [23].
Multiple in vitro studies have revealed that high glucose
leads to increased expression of inflammatory cytokine
genes in primary-derived or cell line-derived monocytes
and macrophages [36–38], as well as increased binding of
monocytes to endothelial cells [37]. Importantly, although
the transcriptional levels of proinflammatory mediators can
be measured in cells exposed to high glucose levels [37], an
actual increased secretion of inflammatory cytokines only
becomes apparent after costimulation, e.g., with phorbol
12-myristate 13-acetate (PMA) [36], LPS or Mycobac-
terium tuberculosis [39, 40]. This suggests that glucose
itself only ‘primes’ monocytes, by inducing (mild) changes
in the transcriptional program, while a clear proinflamma-
tory phenotype only evolves after costimulation with
pathogenic stimuli. Perhaps, monocytes previously exposed
to high glucose levels develop a similar proinflammatory
phenotype after restimulation with pathogenic stimuli,
indicating a memorization of hyperglycemic events.
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Thus, there is strong evidence that chronic hyper-
glycemia, the hallmark of diabetes, is associated with a
(low-grade) activation of the innate immune system,
which, in turn, is associated with accelerated atheroscle-
rosis. The phenomenon of hyperglycemic memory, i.e., the
observation that even transient periods of hyperglycemia
enhance development of atherosclerosis, suggests that
elevated glucose may be somehow memorized and induce
long-term activation of the innate immune system, which
eventually accelerates atherosclerosis development. How-
ever, knowledge on the molecular mechanisms controlling
these processes is lacking. Identifying these pathways may
help in our efforts to find new therapeutic targets to treat or
prevent atherosclerosis.
The concept of trained immunity
in the pathogenesis of atherosclerosis
Recent discoveries in the field of innate immunity may
shed light on how monocytes and macrophages adopt a
long-term proinflammatory phenotype in patients with risk
factors for atherosclerosis. In recent years, it has been
revealed that innate immune cells exhibit an immunologi-
cal (non-specific) memory of past insults, which has been
named ‘‘trained immunity’’ or ‘‘innate immune memory’’
[14, 15]. With respect to host defense toward pathogens,
immune responses in vertebrates were classically divided
into innate (e.g., monocytes and macrophages) and adap-
tive (B- and T-cells), with only the latter being able to build
specific immunological memory. However, this dogma has
been challenged with the discovery that monocytes possess
a non-specific long-term memory that changes their func-
tional program, resulting in protection from reinfection
independent of T and B lymphocytes [41, 42]. Function-
ally, this means that priming of innate immune cells with
an initial (microbial) challenge results in an enhanced
responsiveness to a secondary challenge [14]. This
enhanced responsiveness of monocytes is characterized by
increased production of inflammatory mediators. Mecha-
nistic studies showed that the reprogramming of monocytes
is mediated by epigenetic modifications [14, 42–44].
Importantly, these changes allow for an increased response
to restimulation of cells through both the same and dif-
ferent pattern recognition receptors (PRRs), and can
persists for weeks to months [14]. So far, monocyte
training with fungal cell wall b-glucans, Candida or
Bacillus Calmette–Gue´rin (BCG) is associated with chan-
ges in H3K4me3 at promoters of proinflammatory
cytokines [42], as well as changes in other chromatin
marks, such as H3K4me1, H2K27Ac, and H3K9me2
[43, 45]. In addition to these chromatin marks, other
additional histone modifications or DNA methylation
changes are likely to be involved in the process of trained
immunity, but have not yet been identified.
Although this phenomenon of trained immunity can be
beneficial in the context of infections, long-term activation
of the innate immune system might be detrimental in
chronic inflammatory diseases including atherosclerosis
[46]. Importantly, microbial ‘training’ of monocytes acti-
vates transcriptional programming of various genes
involved in the process of atherosclerosis, including
proinflammatory cytokines, chemokines, and scavenger
receptors, which results in increased foam cell formation
[47, 48]. This implies that circulating monocytes that have
not yet infiltrated the plaque are exposed to environmental
signals that may induce epigenetic reprogramming of the
cells, which, in turn, makes them more responsive toward a
second stimulus, e.g., within the atherosclerotic plaques.
Importantly, the induction of trained immunity is not
restricted to microbial products, since oxidized LDL
(oxLDL) can also induce trained immunity and long-term
atherosclerotic properties of monocytes via similar epige-
netic modifications in vitro [48]. The training of monocytes
by oxLDL implies that monocytes previously exposed in
circulation are particularly prone to develop into proin-
flammatory cells, or foam cells, once entering the arterial
wall. The training efficacy of other endogenous compounds
associated with metabolic diseases, including cholesterol
crystals, free fatty acids (FFAs), and advanced glycation
end products (AGEs), remains unknown. Importantly, these
compounds are known to induce an (low-grade) inflam-
matory response in monocytes via activation of various
PRRs [49–51]. Whether they additionally have the poten-
tial to epigenetically reprogram monocytes and, thereby,
modify their long-term (proinflammatory) behavior,
remains to be established [47].
Clinical evidence for the concept of trained immunity in
coronary artery disease has been recently provided by the
study of Shirai et al. This study evaluated whether mono-
cytes derived from patients with coronary artery disease are
primed differently, resulting in proinflammatory cytokine
production upon entering the tissue space, by comparing
ex vivo-differentiated macrophages from patients and
controls [52]. Patient-derived monocytes showed increased
production of proinflammatory cytokines IL-6 and IL-1b
after stimulation, which persisted once cells differentiated
into macrophages, suggesting a different reprogramming of
the cells. Further studies are required to determine the role
of chromatin modifications in this persistent gene
expression.
Collectively, the long-term memory of innate immune
cells mediated by epigenetic reprogramming has important
implications for our understanding of the pathogenesis of
atherosclerosis, although solid clinical evidence is still
needed. In addition, further studies are required to evaluate
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the concept of trained immunity in response to other
metabolites associated with metabolic disease. AGEs and
high glucose levels that are increased in patients with
diabetes represent interesting candidates to evaluate whe-
ther trained immunity could be an underlying mechanisms
involved in the phenomenon of hyperglycemic memory.
Can trained immunity contribute
to atherosclerosis in diabetes patients?
The identification of oxLDL as an inducer of trained
immunity suggests a role for metabolic endogenous com-
pounds in training of monocytes, potentially unraveling
epigenetic reprogramming of monocytes as a novel patho-
genic pathway contributing to atherosclerotic development.
Importantly, this opens new avenues for future research to
explore the contribution of trained immunity to the phe-
nomenon of hyperglycemic memory in patients with
diabetes. Shirai et al. revealed that various risk factors for
coronary events, i.e., hypertension, hyperlipidemia, and
T2D all correlated with IL-6 release by monocytes ex vivo,
showing considerable potential for exploration of other
atherogenic risk factors that could induce training of
monocytes [52]. A previous study showed that monocytes
obtained from T2D patients displayed enhanced inflamma-
some activation [24]. Moreover, after differentiation to
macrophages ex vivo, cells from T2D patients showed an
enhanced cytokine secretion in response to the bacterial
components LPS and Pam3Cys [24]. This study implies that
the diabetic milieu reprograms the function of circulating
monocytes that have not yet infiltrated the atherosclerotic
plaque, which may lead to a more proinflammatory pheno-
type after differentiation or ex vivo culture. Hence,
translating these ex vivo observations to the in vivo situa-
tion, reprogrammed monocytes recruited to the
atherosclerotic plaques may develop into more proathero-
genic macrophages and accelerate the development of CVD.
We hypothesize that hyperglycemic conditions in dia-
betes patients induces training of monocytes, functionally
reprogramming the monocytes to display a more ‘aggres-
sive’ proatherosclerotic response to subsequent encounter
with other stimuli (e.g., cytokines and oxLDL). We pro-
pose that this process contributes to the phenomenon of
hyperglycemic memory, resulting in enhanced plaque
development and subsequent macrovascular complications
(Fig. 1). Endogenous ‘training’ stimuli in diabetes patients,
as well as mechanisms that confer the cell memory are so
far unknown and remain to be established. In the remainder
of this review, we discuss stimuli and pattern recognition
receptors that may be involved in reprogramming of
monocytes in patients with diabetes. In addition, we
describe epigenetic changes that have been observed in
monocytes from diabetes patients, and possibly contributed
to proatherosclerotic reprogramming of these monocytes.
Finally, we describe immunometabolic processes that are
activated in trained innate immune cells, and may con-
tribute to training of cells by hyperglycemic conditions.
Training stimuli and pattern recognition receptors
Activation of recognition receptors on the surface of innate
immune cells is likely to play a central role in innate
immune memory [53, 54]. Several pattern-recognition
receptors [PRRs; e.g., Toll-like receptors (TLRs) and
C-type lectin receptors (CLRs)] of the innate immune
system are involved in translating pattern-associated
molecular patterns and (endogenous) danger signals to
cellular responses, including training of monocytes [14].
Specific activation of the CLR Dectin-1 is involved in
training of monocytes, resulting in enhanced proinflam-
matory cytokine secretion and foam cell formation
[42, 48]. Multiple innate immune receptors including
TLR2, TLR4, Mincle, NOD1/2, and NLRP3 are implicated
in the recognition of dietary factors and endogenous danger
signals, which translates into innate immune receptor sig-
naling and inflammation in response to metabolic stress
[55–57]. For example, free fatty acids are known to
enhance TLR signaling, leading to activation of proin-
flammatory pathways [49]. CLRs are much less studied in
relation to ‘metabolic inflammation’. CLRs are trans-
membrane receptors characterized by the presence of a
carbohydrate-binding domain and highly expressed by
macrophages. Macrophage-inducible CLRs such as Mincle
or C-type Lectin 4e (Clec4e) recognize endogenous ligands
from dying adipocytes and affect macrophage function in
adipose tissue [56]. CLRs recognize carbohydrate struc-
tures present on pathogens [58]. It could be hypothesized
that CLRs may also be able to recognize similar carbohy-
drate structures on endogenous (so far unknown) ligands in
hyperglycemic/diabetic patients, such as AGEs. Within this
respect, it is interesting that expression of the CLR Dectin-
1 is increased on circulating monocytes from patients with
diabetes as compared to healthy controls [59].
Collectively, PRRs and especially CLRs could perhaps
translate hyperglycemic conditions into an elevated risk for
the development of atherosclerosis via induction of trained
immunity in monocytes. Involvement of individual PRRs,
such as Dectin-1, as well as potential endogenous ligands
that are known to be present under hyperglycemic condi-
tions, such as AGEs, needs further evaluation.
Epigenetic modifications
Immunological studies have shown that long-term repro-
gramming of monocytes is mediated by epigenetic changes
Diabetes propels the risk for cardiovascular disease: sweet… 4679
123
[42, 43]. Whether hyperglycemia induces similar ‘‘train-
ing’’ and epigenetic changes in innate immune cells driving
atherosclerotic development remains to be established. In
mice, it has been shown that transient hyperglycemia
induces H3K4me1 and reduces H3K9 demethylation in the
promoter of the NF-jB in aortic endothelial cells, which
associated with increased expression of monocyte
chemoattractant protein-1 (MCP-1) and vascular cell
adhesion molecule 1 (VCAM-1) and persisted for at least
6 days in vitro [60, 61]. In addition, other cell types,
including vascular smooth muscle, retinal, and cardiac
cells, respond to prior episodes of hyperglycemia with
epigenetic changes [12, 13, 62]. Thus, strong evidence
exists that hyperglycemic conditions can induce epigenetic
reprogramming that alters expression of genes involved in
the pathophysiology of diabetes complications [11, 12].
There are a few studies in primary monocytes derived from
diabetes patients at risk for long-term complications. The
first evidence for chromatin rearrangements in monocytes
of diabetes patients came from Miao et al. showing
increased histone H3 lysine 9 (H3K9) acetylation at the
TNF and COX-2 promoter in monocytes from T1D and
T2D patients [63]. Using chip-on-chip analysis, they
additionally identified changes in lysine methylation [his-
tone H3 lysine 4 dimethylation (H3K4me2) and histone H3
lysine 9 dimethylation (H3K9me2)] in proinflammatory
genes in THP-1 monocytes induced by high glucose [63].
The first evidence for the presence of epigenetic histone
posttranslational modifications in monocytes of diabetes
patients comes from analysis of monocytes isolated from
uncontrolled versus controlled T1D patients, a subgroup of
patients from the DCCT/EDIC trial. Monocytes from
uncontrolled conventionally treated subjects ([9.1 %
Hba1c during DCCT) versus intensively treated subjects
(\7.3 % HbA1c during DCCT) were recently assessed for
H3K9Ac, H3K4Me3, and H3K9Me2. Importantly, mono-
cytes from uncontrolled type 1 diabetes patients showed an
increased acetylation of H3K9Ac in promoters of genes
related to inflammatory pathways [64]. In addition, the
methyltransferase Set7 may play a role in epigenetic reg-
ulation of NF-jB under hyperglycemic conditions, since
Set7 is upregulated in monocytes from T2D and associates
with fasting plasma glucose and HbA1c, as well as
H3K4m1 of the NF-jB promoter region and expression of
NF-jB target genes [65]. Evidence for persistence of epi-
genetic changes over time has only recently been shown by
measuring epigenetic DNA methylation alterations in
whole blood derived from a DCCT/EDIC subcohort, while
comparing genomic DNA from intensively and conven-
tionally treated patients before and after the EDIC follow-
up [66]. Indeed, common differentially methylated loci
were found, including changes in thioredoxin-interacting
protein (TXNIP) known to be associated with hyper-
glycemia [66].
While there is evidence that certain epigenetic changes
occur in monocytes of patients with diabetes and can per-
sist over time, it remains to be proved that these are
causally related to a proinflammatory, proatherogenic
phenotype of monocytes, and subsequent cardiovascular
complications. Moreover, the mechanisms by which epi-
genetic changes are induced in monocytes exposed to high
glucose levels remain to be established.
Fig. 1 Schematic representation of the concept that hyperglycemia
induces ‘trained immunity’ in monocytes. Initial stimulation of
monocytes by hyperglycemic conditions (i.e., glucose or AGEs)
induces epigenetic reprogramming of monocytes. The reprogramming
of monocytes results in a long-term activated phenotype and
increased response to a subsequent stimulus (e.g., oxLDL or
cytokines). The more ‘aggressive’ proatherosclerotic response is
characterized by, e.g., increased proinflammatory cytokine secretion
and foam cell formation. AGE advanced glycation end products, Mf
macrophage, Mo monocytes, oxLDL oxidized LDL
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Intracellular metabolism
Recent interest and research focus on the direct relation
between metabolism and chromatin dynamics [67], which
would be an interesting concept to study in the context of
epigenetic changes induced by high glucose exposure,
especially because recent studies revealed that intracellular
metabolism of glucose highly determines the activation
status of innate immune cells during acute activation [68]
as well as long-term activation of monocytes via trained
immunity [45]. Upon an acute inflammatory stimulus, the
cellular metabolism of an immune cell undergoes profound
changes [69]. More specifically, whereas activation of
glycolysis is associated with proinflammatory status of an
immune cell, oxidative phosphorylation is mostly associ-
ated with an anti-inflammatory profile. Assuming that
chronic hyperglycemia increases glucose availability as a
substrate for innate immune cells, it could be hypothesized
that high circulating glucose levels stimulate glucose uti-
lization via glycolysis, thereby reprogramming innate
immune cells toward a more proinflammatory phenotype.
Indeed in vitro, the absence of the glucose transporter 1
(GLUT1) reduces both glycolysis and proinflammatory
cytokine secretion [70, 71]. Vice versa, increased glycol-
ysis induced by overexpression of GLUT1 leads to
enhanced proinflammatory cytokine secretion [70]. How-
ever, in an experimental model in vivo, the increased
glucose uptake did not stimulate inflammatory activation of
peritoneal cells upon ex vivo stimulation with LPS, neither
did it affect the development of atherosclerosis in Ldlr-/-
mice in vivo [71], suggesting that increased glucose supply
alone is not sufficient to drive inflammatory activation and
atherosclerosis in non-activated myeloid cells [72]. Possi-
bly, synergism of glycolysis with other metabolic or
immunologic pathways is necessary to induce the inflam-
matory phenotype in monocytes.
Recent data show that monocytes and macrophages of
patients with atherosclerotic coronary artery disease dis-
play overutilization of glucose, promoting excessive and
prolonged production of proinflammatory cytokines [52].
These data support the hypothesis that increased utiliza-
tion of glucose is involved in reprogramming of innate
immune cells toward a proinflammatory, proatherogenic
phenotype. Whether this is exacerbated under hyper-
glycemic conditions is so far unknown and requires
further investigation. Nevertheless, reducing glycolysis
corrects the proinflammatory phenotype of macrophages
derived from patients with atherosclerotic coronary artery
disease [52]. In addition, a reduction in glycolysis in
myeloid cells via GLUT1 deletion inhibits expansion and
proliferation of myeloid progenitor cells, leading to a
reduction of plaque macrophages in an animal model for
atherosclerosis in vivo [73].
An important molecular switch that drives cellular
metabolism in macrophages is AMP-activated protein
kinase (AMPK) [68]. Importantly, activation of AMPK has
been demonstrated to exert anti-inflammatory effects [68].
Metformin is a glucose lowering drug that activates AMP-
activated protein kinase (AMPK) in vitro and reduces
redox shuttle enzyme mitochondrial glycerophosphate
dehydrogenase [74, 75]. Metformin has been shown to
inhibit the process of trained immunity induced by b-glu-
can [45]. Interestingly, metformin treatment of T2D
patients increases AMPK activation in monocyte-derived
macrophages [24]. Moreover, metformin treatment reduced
T2D monocyte activation, measured by a reduction in
inflammasome activation and IL-1b secretion ex vivo [24].
These data suggest that metformin can reduce ‘training’ of
monocytes that has initially been induced by a diabetic
environment. Such properties may contribute to the
demonstrated beneficial effects of metformin on cardio-
vascular outcomes in patients with diabetes.
In sum, the long-term reprogramming of monocytes by
pathogenic stimuli involves a shift in cellular metabolism
from oxidative phosphorylation to aerobic glycolysis. We
hypothesize that hyperglycemia in diabetes patients indu-
ces long-term activation of monocytes and macrophages
through similar mechanisms, thereby contributing to pla-
que development and subsequent macrovascular
complications.
Concluding remarks and future directions
Chronically elevated glucose levels are one of the main risk
factors for CVD, rendering blood glucose control of utmost
importance. However, the hyperglycemic memory induced
by previous episodes of uncontrolled blood glucose levels
limits subsequent effectiveness of glucose control to pre-
vent long-term CVD complications. High glucose levels
might prime innate immune cells and change their epige-
netic profile to a predisposed proinflammatory state,
referred to as ‘‘trained immunity’’ ultimately promoting
atherosclerotic plaque development. Effectiveness of glu-
cose lowering therapies in diabetes patients may suffer
from such training effects, reducing effectiveness because
of an imprinted proinflammatory response.
While compelling new data suggest that this effect of
hyperglycemia on long-term functional reprogramming of
monocytes and macrophages is important in the patho-
physiology of atherosclerosis in patients with diabetes,
many crucial factors remain to be explored. First, the life
span of circulating monocytes ranges from days to weeks,
while deleterious effects of exposure to hyperglycemia
persist for years after implementation of improved gly-
cemic control. It may well be that elevated glucose levels
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already induce ‘training’ and (epigenetic) changes in
hematopoietic stem cells (HSCs) within the bone marrow.
Recent evidence from diabetes animal models character-
ized by high glucose levels indeed shows alterations in
HSCs—including epigenetic changes and a prolonged
intrinsic proinflammatory phenotype [23, 76, 77]. Other
factors that remain to be explored are the causality between
specific epigenetic changes and the functional and clinical
complications; the potential roles of epigenetic mecha-
nisms additional to chromatin structure and histone
modifications such as long non-coding RNAs; the molec-
ular switches leading to these changes, and identification of
novel strategies to correct the long-term immune activation
to improve the outcome of the patients. Only when these
steps have been undertaken, the full impact of these dis-
coveries becomes available.
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